Biohaven Ltd is a biopharmaceutical company that focuses on developing innovative treatments for neurological and rare disorders. By harnessing advanced scientific research and drug development expertise, Biohaven aims to address unmet medical needs through their portfolio of promising therapies. The company's commitment to improving patient outcomes is reflected in their efforts to bring new, effective medications to market, particularly for conditions such as migraine and neurodegenerative diseases. Through rigorous clinical trials and a dedication to scientific excellence, Biohaven strives to enhance the quality of life for individuals affected by debilitating health issues. Read More
NEW YORK - September 3, 2025 ( NEWMEDIAWIRE ) - Levi & Korsinsky, LLP notifies investors in Biohaven Ltd. (NYSE: BHVN) of a class action securities lawsuit.
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Biohaven To Contact Him Directly To Discuss Their Options
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Biohaven (BHVN) To Contact Him Directly To Discuss Their Options
NEW YORK, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Biohaven Ltd. (“Biohaven” or the “Company”) (NYSE: BHVN) and certain officers. The class action, filed in the United States District Court for the District of Connecticut, and docketed under 25-cv-01120, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Biohaven securities between March 24, 2023 and May 14, 2025, both dates inclusive (the “Class Period”), seeking to recover damages caused by Defendants’ violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 sand Rule 10b-5 promulgated thereunder, against the Company and certain of its top officials.
NEW YORK - September 2, 2025 ( NEWMEDIAWIRE ) - Levi & Korsinsky, LLP notifies investors in Biohaven Ltd. (NYSE: BHVN) of a class action securities lawsuit.
If you purchased or acquired securities in any of the above companies during their class period and would like to discuss your legal rights, call Bragar Eagel & Squire partner Brandon Walker or Marion Passmore directly at (212) 355-4648
Rosen Law Firm, a global investor rights law firm, reminds investors that a shareholder filed a class action on behalf of purchasers of securities of Biohaven Ltd. (NYSE: BHVN) between March 24, 2023 and May 14, 2025. Biohaven describes itself as a “biopharmaceutical company that discovers, develops, and commercializes therapies for immunology, neuroscience, and oncology.”
NEW YORK, Aug. 29, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Biohaven Ltd. (“Biohaven” or the “Company”) (NYSE: BHVN) and certain officers. The class action, filed in the United States District Court for the District of Connecticut, and docketed under 25-cv-01120, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Biohaven securities between March 24, 2023 and May 14, 2025, both dates inclusive (the “Class Period”), seeking to recover damages caused by Defendants’ violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 sand Rule 10b-5 promulgated thereunder, against the Company and certain of its top officials.
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Biohaven To Contact Him Directly To Discuss Their Options
NEW YORK - August 28, 2025 ( NEWMEDIAWIRE ) - Levi & Korsinsky, LLP notifies investors in Biohaven Ltd. (NYSE: BHVN) of a class action securities lawsuit.
NEW YORK - August 27, 2025 ( NEWMEDIAWIRE ) - Levi & Korsinsky, LLP notifies investors in Biohaven Ltd. (NYSE: BHVN) of a class action securities lawsuit.
NEW YORK - August 26, 2025 ( NEWMEDIAWIRE ) - Levi & Korsinsky, LLP notifies investors in Biohaven Ltd. (NYSE: BHVN) of a class action securities lawsuit.
If you purchased or acquired securities in any of the above companies during their class period and would like to discuss your legal rights, call Bragar Eagel & Squire partner Brandon Walker or Marion Passmore directly at (212) 355-4648
NEW YORK, Aug. 25, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Biohaven Ltd. (“Biohaven” or the “Company”) (NYSE: BHVN) and certain officers. The class action, filed in the United States District Court for the District of Connecticut, and docketed under 25-cv-01120, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Biohaven securities between March 24, 2023 and May 14, 2025, both dates inclusive (the “Class Period”), seeking to recover damages caused by Defendants’ violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 sand Rule 10b-5 promulgated thereunder, against the Company and certain of its top officials.
NEW YORK - August 25, 2025 ( NEWMEDIAWIRE ) - Levi & Korsinsky, LLP notifies investors in Biohaven Ltd. (NYSE: BHVN) of a class action securities lawsuit.
NEW YORK - August 22, 2025 ( NEWMEDIAWIRE ) - Levi & Korsinsky, LLP notifies investors in Biohaven Ltd. (NYSE: BHVN) of a class action securities lawsuit.
